Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.

Juliana de Oliveira Costa Jialing Lin Tamara Y Milder Jerry R Greenfield Richard Osborne Day Sophie Lena Stocker Brendon L Neuen Alys Havard Sallie-Anne Pearson Michael O Falster

Published in: Diabetes, obesity & metabolism (2024)

The prevalence of SGLT2i and GLP-1RA use varied by geography, probably reflecting a combination of system- and prescriber-level factors. Socio-economic variation in GLP-1RA use was overshadowed by localized patterns of prescribing. Continued monitoring of variation can help shape interventions to optimize use among people who would benefit the most.

Keyphrases

rheumatoid arthritis
primary care
risk factors
physical activity
ankylosing spondylitis
emergency department
systemic lupus erythematosus
drug induced